15 recruiting, 12 unknown, 5 completed, 5 not yet recruiting. 23 Phase 2, 13 Phase 3, 8 Phase 1, 2 Not applicable.
Follow Cisplatin injection: new trials by email Literature Review of Cisplatin injection trials Research Report on Cisplatin injection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NEC LBL-024 for Injection, Etoposide injection, Cisplatin injection - Advanced Extrapulmonary Neuroendocrine Carcinoma | Phase 3 | Not yet recruiting | Nanjing Leads Biolabs Co.,Ltd | 280 | 2026-11-16 | 2026-10-19 |
| ZG005 Plus Etoposide and Cisplatin vs. Etoposide and Cisplatin as First-Line Treatment for Advanced Neuroendocrine Carcinoma ZG005 for Injection, Etoposide Injection, Cisplatin Injection - Neuroendocrine Carcinomas (NEC) | Phase 3 | Not yet recruiting | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 440 | 2026-10-01 | 2026-09-22 |
| A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)] LBL-024 for Injection, Cisplatin Injection, Paclitaxel Injection - Advanced Solid Tumour | Phase 2 | Recruiting | Nanjing Leads Biolabs Co.,Ltd | 110 | 2026-02-26 | 2026-05-18 |
| A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC) SHR-8068 Injection, Adebrelimab Injection, Gemcitabine Hydrochloride for Injection - Advanced Biliary Tract Cancer | Phase 3 | Recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 604 | 2026-01-21 | 2026-01-28 |
| Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer Pemetrexed injection, Carboplatin Injection, Cisplatin injection - Non Squamous Non-small Cell Lung Cancer | Phase 3 | Not yet recruiting | Shanghai Huaota Biopharmaceutical Co., Ltd. | 500 | 2026-01-15 | 2026-02-03 |
| A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors SHR-7787 Injection, SHR-1316 Injection, SHR-4849 Injection - Malignant Solid Tumors | Phase 2 | Recruiting | Shanghai Hengrui Pharmaceutical Co., Ltd. | 400 | 2025-12-23 | 2026-01-12 |
| A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)] LBL-024 for Injection, Cisplatin Injection, Gemcitabine Hydrochloride for Injection - Advanced Solid Tumour | Phase 2 | Recruiting | Nanjing Leads Biolabs Co.,Ltd | 140 | 2025-10-20 | 2026-10-19 |
| A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer SHR-1316 Injection, Cisplatin Injection, Carboplatin Injection - Advanced Cervical Cancer | Phase 3 | Recruiting | Shanghai Shengdi Pharmaceutical Co., Ltd | 720 | 2025-10-17 | 2026-04-15 |
| SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer SHR-A1811, Adebelimab injection, Bevacizumab injection - Recurrent or Metastatic Cervical Cancer | Phase 1 / Phase 2 | Recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 100 | 2025-04-25 | 2025-06-06 |
| Neoadjuvant Immunochemotherapy in PD-L1-negative LACC Camrelizumab, Paclitaxel-albumin, Cisplatin - Cervical Cancer, Locally Advanced Cervical Cancer | Phase 2 | Recruiting | Tongji Hospital | 40 | 2024-09-12 | 2025-03-20 |
| Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer Cadonilimab, Paclitaxel-albumin, Cisplatin - Cervical Cancer, Neoadjuvant Chemoimmunotherapy | Phase 2 | Recruiting | Tongji Hospital | 50 | 2024-09-03 | 2024-09-19 |
| Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations BEBT-109 Capsules, Pemetrexed Disodium for Injection, Carboplatin Injection - Non Small Cell Lung Cancer | Phase 2 | Recruiting | BeBetter Med Inc | 30 | 2024-08-28 | 2026-08-18 |
| A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer SHR-A2102 for Injection, Adebrelimab Injection, Cisplatin injection - Advanced or Metastatic Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Shanghai Hengrui Pharmaceutical Co., Ltd. | 248 | 2024-07-30 | 2025-12-23 |
| JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations JMT101 Injection, Osimertinib tablet, Cisplatin injection - Local Advanced or Metastatic NSCLC | Phase 3 | Not yet recruiting | Shanghai JMT-Bio Inc. | 398 | 2024-04-26 | 2024-04-23 |
| PD-L1/PD-1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone for the Neoadjuvant Treatment of Limited-stage SCLC Tislelizumab, Carboplatin injection, Cisplatin injection - Limited-stage Small-cell Lung Cancer | Phase 2 | Not yet recruiting | Beijing Chest Hospital, Capital Medical University | 60 | 2024-04-16 | 2024-04-19 |
| Dose Escalation Using Hypoxia-adjusted Radiotherapy DE-HyART, Standard Arm, Cisplatin injection - Head and Neck Squamous Cell Carcinoma | Phase 2 | Recruiting | Rajiv Gandhi Cancer Institute & Research Center, India | 124 | 2024-04-08 | 2025-01-17 |
| A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma LBL-024 for Injection, Etoposide Injection, Carboplatin Injection - Advanced Neuroendocrine Carcinoma | Phase 1 / Phase 2 | Recruiting | Nanjing Leads Biolabs Co.,Ltd | 178 | 2023-12-08 | 2026-03-12 |
| A Trial of TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the First-line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer TQB2868 injection, Paclitaxel injection, Cisplatin injection - Cervical Cancer | Phase 2 | Withdrawn | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2023-08-01 | 2023-11-22 | |
| Combined Therapy Using D-TACE, Gemcitabine and Cisplatin, and PD1 Antibody in Advanced and Unresectable Intrahepatic Cholangiocarcinoma Camrelizumab, Gemcitabine Injection, Cisplatin injection - Unresectable Intrahepatic Cholangiocarcinoma | Phase 2 | Unknown | Hua Li | 22 | 2023-06-30 | 2023-11-29 |
| Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC serplulimab, Cisplatin, Carboplatin - Extensive-stage Small-cell Lung Cancer | Phase 2 | Active not recruiting | Sichuan University | 61 | 2023-03-07 | 2026-04-29 |
Showing 20 of 42. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (6) · Uterine Cervical Neoplasms (6) · Small Cell Lung Carcinoma (4) · Head and Neck Neoplasms (3) · Nasopharyngeal Carcinoma (3) · Carcinoma, Neuroendocrine (2) · Neoplasms (2) · Oropharyngeal Neoplasms (2) · Recurrence (2) · Squamous Cell Carcinoma of Head and Neck (2) · Carcinoma, Squamous Cell (1) · Carcinoma, Transitional Cell (1) · Cardiotoxicity (1) · Deglutition Disorders (1) · Esophageal Neoplasms (1)
Nanjing Leads Biolabs Co.,Ltd (5) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (3) · Shanghai Hengrui Pharmaceutical Co., Ltd. (2) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. (2) · Tongji Hospital (2) · Ain Shams University (1) · BeBetter Med Inc (1) · BeiGene (1) · Beijing Chest Hospital, Capital Medical University (1) · Centre Hospitalier Universitaire Dijon (1) · Guangzhou Double Bioproducts Co., Ltd (1) · Hua Li (1) · Institut du Cancer de Montpellier - Val d'Aurelle (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · Jules Bordet Institute (1)
China (31) · France (2) · United States (2) · Australia (1) · Belgium (1) · Canada (1) · Egypt (1) · India (1) · New Zealand (1) · United Kingdom (1)
Ding Ma (2) · Lin Shen (2) · Caicun Zhou, MD (1) · Dong Wang, PH.D (1) · Dongqing Lv, MD (1) · Gregory Biedermann, MD (1) · Huiqiang Huang, Ph.D (1) · Li Zhang, M.D. (1) · Li Zhang, Master (1) · Michael Penniment, FRANZCR (1) · Munish Gairola, MD,DNB Radiation Oncology (1) · Renmiao Zhang, MD, PhD (1) · Riou Olivier, MD (1) · Siddharth Sheth, DO, MPH (1)
PMID 16763816, PMID 17426445, PMID 17448882, PMID 17869020, PMID 24662947, PMID 28249612, PMID 29248399, PMID 35395276, PMID 36539781, PMID 39581197, PMID 40233976, PMID 40949474, PMID 41344593, PMID 41582028, PMID 42164114